Correction: Marizomib in the therapy of brain tumors—how far did we go and where do we stand?

Correction: Pharmacological Reports

10.1007/s43440-025-00739-0

In Table 1 of this article, images in the second column "Structure" were incorrectly arranged.

Table 1.

A summary of the main properties of key proteasome inhibitors based on their chemical structure and mechanism of action.

Proteasome inhibitor	Structure	Chemical origin	Inhibition	Targeted protea-some subunit	Administration	Class	Half-life/ applied dosage	References
Bortezomib (PS-341)		Boronate	Reversible	CT-L	Intravenous, Subcutaneous	I	110 min (1 µmol/L for 30 min) up to 6.8 h (1 mg/m2, first day)-32.5 h (1 mg/m2, eleventh day)*	[18, 27, 52]
Ixazomib (MLN9780/ MLN2238)		Boronate	Reversible	CT-L	Intravenous, Oral	I	18 min (1 µmol/L for 30 min) up to 3.6–11.3 days (once weekly 0.8–3.95 mg/m2)*	[27, 53, 54]
Delanzomib (CEP-18770)		Boronate	Reversible	CT-L	Intravenous, Subcutaneous, Oral	I	62 h (0.1–1.8 mg/m2)	[28, 30, 55]
Carfilzomib (PR-171)		Epoxy-ketone	Irreversible	CT-L	Intravenous	II	< 60 min (2–8 mg/kg)	[29, 39, 56]
Oprozomib (ONX0912/ PR-047)		Epoxyk-etone	Irreversible	CT-L	Intravenous, Oral	II	< 90 min (30 mg/kg)	[29, 39, 57]
Marizomib (salinosporamide A/ NPI-0052)		β-lactone	Irreversible	CT-L, T-L, C-L	Intravenous, Oral	II	< 30 min (0.3–0.8 mg/m2)	[50]

*The reported values of the half-life vary dependently on the administrated dose, therapy regimen, duration of treatment and the day of sample collection

The original article has been corrected.